نبذة مختصرة : Biologically active molecules, such as carbohydrates, peptides, and proteins, are attractive candidates for positron emission tomography (PET) imaging because of their strong target affinity and biocompatibility. Among available radionuclides, fluorine-18 ( 18 F) is widely used in clinical practice because of its moderate half-life and high-quality imaging properties. However, traditional 18 F-labeling methods often require a laborious procedure and harsh conditions, which may compromise the structural integrity and biological functions. Developing mild and efficient 18 F-labeling strategies is therefore critical for advancing biomolecular PET tracers. In this study, we developed a novel clickable 18 F-labeled synthon, 1-ethynyl-3-([ 18 F]trifluoromethyl)-5-(trifluoromethyl)benzene ([ 18 F] 1 ), prepared via an 18 F/ 19 F isotope exchange reaction (RCY = 17.2 ± 3.9%). [ 18 F] 1 exhibited excellent performance in copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC) conjugation, enabling rapid and chemoselective labeling of azide-modified glucose derivatives, Arg-Gly-Asp (RGD) and cyclic RGD (cRGD) peptides, and phospholipids under mild conditions. PET imaging in U87 MG, 4T1, and BT474 xenograft models showed favorable tumor uptake for both [ 18 F] 5a and [ 18 F] 5b , peaking at 30 min postinjection. Tumor accumulation for [ 18 F] 5a reached 3.11 ± 0.21, 2.40 ± 0.17, and 1.95 ± 0.09% ID/g in U87 MG, 4T1, and BT474 models, respectively, while [ 18 F] 5b achieved higher values of 5.19 ± 0.42, 4.90 ± 0.97, and 2.05 ± 0.11% ID/g at the same time pointconsistent with the superior binding affinity of cRGD. Tumor-to-muscle ratios were favorable, with[ 18 F] 5b reaching 4.32 ± 0.39 in the 4T1 model. Blocking studies in U87 tumors confirmed high binding specificity, with uptake reduced to approximately 1% ID/g. This isotope exchange-based CuAAC labeling strategy streamlines PET tracer synthesis, preserves biomolecule integrity, and offers a versatile platform for molecular imaging and pretargeting applications.
No Comments.